Evaluation of Post-thrombolytic Events to Determine Appropriate ICU Monitoring Duration for Patients with Ischemic Stroke
ConclusionsOur study demonstrates that sICH, neurological deterioration, and need for ICU intervention rarely occur beyond 12 h after thrombolytic administration. Patients presenting with blood pressures < 140/90 mm Hg, NIHSS scores < 10, and not undergoing mechanical thrombectomy may be best candidates for early de-escalation. Larger prospective studies are needed to more fully evaluate the safety, feasibility, and financial impact of early transition out of the ICU. (Source: Neurocritical Care)
Source: Neurocritical Care - April 8, 2024 Category: Neurology Source Type: research
Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study
CONCLUSION: We found that the risk of bleeding in patients taking Crude low molecular weight heparins was significantly higher compared to other antithrombotic agents, but with a small magnificence, which may be attributed to the severely irrational use of this medication under improper management. Statistics in days, results showed that the risk of bleeding decreased over time for warfarin and clopidogrel and increased for alteplase, nadroparin, and dipyridamole.PMID:38497691 | DOI:10.1080/14740338.2024.2327502 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 18, 2024 Category: Drugs & Pharmacology Authors: Kangyuan Guo Ganyi Wang Li Zhang Zhanchun Feng Xudong Xia Xiaobo Sun Ziqi Yan Zhiming Jiao Da Feng Source Type: research
Hemorrhagic bullae and necrotic ulcerations associated with Alteplase extravasation
(Source: Neurological Sciences)
Source: Neurological Sciences - March 15, 2024 Category: Neurology Source Type: research
NIR Light ‐Fuse Drug‐Free Photothermal Armor‐Piercing Microcapsule for Femoral Vein Thrombosis Therapy
In conclusion, this study demonstrates that the drug-free armor-piercing microcapsule has significant potential in the treatment of thrombosis, offering a safe and effective alternative to traditional thrombolytic therapies. (Source: Small)
Source: Small - March 15, 2024 Category: Nanotechnology Authors: Ning Yang,
Zhicheng Qian,
Renqiang Yuan,
Weikun Li,
Xin Tan,
Zonghao Liu,
Qianli Zhang,
Liqin Ge,
Ling Liu Tags: Research Article Source Type: research
Inconclusive Findings in Non-Vitamin K Antagonist Oral Anticoagulants Study
To the Editor In their population-based cohort study using Taiwan ’s National Health Insurance Research Database, Tsai et al report no excess risk of intracranial hemorrhage (ICH) associated with treatment compared with no treatment with non-vitamin K antagonist oral anticoagulants (NOACs) in patients with acute ischemic stroke receiving intravenous alteplase. W e applaud the authors’ efforts to build on the evidence on the safety of thrombolysis in patients receiving NOACs; however, we wonder about potential issues of exposure and outcome misclassification producing results that are biased toward the null hypothesis. ...
Source: JAMA Internal Medicine - March 11, 2024 Category: Internal Medicine Source Type: research
Inconclusive Findings in Non-Vitamin K Antagonist Oral Anticoagulants Study
To the Editor We read with interest the nationwide population-based cohort study with meta-analysis by Tsai et al. The study findings showed that patients who received non-vitamin K antagonist oral anticoagulants (NOACs) before a stroke, compared with those receiving warfarin and those without oral anticoagulant treatment (non-OAC), did not experience a higher risk of intracranial hemorrhage (ICH), major bleeding events, or mortality when treated with intravenous alteplase for acute ischemic stroke. In comparison with the active comparator (warfarin group), the odds ratios (ORs) were 0.88 (95% CI, 0.32-2.40) for ICH, 0.82 ...
Source: JAMA Internal Medicine - March 11, 2024 Category: Internal Medicine Source Type: research
Effect of Clot Burden Score on Safety and Efficacy of Intravenous Alteplase Prior to Mechanical Thrombectomy in Acute Ischemic Stroke: A Subgroup Analysis of a Randomized Phase 3 Trial [NEUROVASCULAR/STROKE IMAGING]
CONCLUSIONS:
The subgroup analysis of DIRECT-MT suggested that thrombus burden did not alter the treatment effect of IVT before MT on functional outcomes in CBS subgroups. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - March 7, 2024 Category: Radiology Authors: Li, Z., Zhou, Y., Zhang, X., Zhang, L., Zhang, Y., Xing, P., Zhang, Y., Huang, Q., Li, Q., Zuo, Q., Ye, X., Liu, J., Yang, P., on behalf of DIRECT-MT Investigators Tags: NEUROVASCULAR/STROKE IMAGING Source Type: research
Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials
CONCLUSIONS: Among AIS patients, there was no significant difference on clinical outcomes between tenecteplase and alteplase. Subgroup analysis demonstrated that 0.25 mg/kg doses of tenecteplase were more beneficial than 0.4 mg/kg doses of tenecteplase. Further studies are required to identify the optimal dosage of tenecteplase.PMID:38442293 | DOI:10.1080/07853890.2024.2320285 (Source: Annals of Medicine)
Source: Annals of Medicine - March 5, 2024 Category: Internal Medicine Authors: Jian Huang Hui Zheng Xianfeng Zhu Kai Zhang Xiaofeng Ping Source Type: research
Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials
CONCLUSIONS: Among AIS patients, there was no significant difference on clinical outcomes between tenecteplase and alteplase. Subgroup analysis demonstrated that 0.25 mg/kg doses of tenecteplase were more beneficial than 0.4 mg/kg doses of tenecteplase. Further studies are required to identify the optimal dosage of tenecteplase.PMID:38442293 | PMC:PMC10916912 | DOI:10.1080/07853890.2024.2320285 (Source: Annals of Medicine)
Source: Annals of Medicine - March 5, 2024 Category: Internal Medicine Authors: Jian Huang Hui Zheng Xianfeng Zhu Kai Zhang Xiaofeng Ping Source Type: research
Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies
ConclusionsModerate certainty evidence suggested that there was little to no difference between tenecteplase and alteplase in increasing the proportion of patients achieving excellent functional outcome at 3 months and the risk of symptomatic intracranial hemorrhage, while compared to alteplase, tenecteplase probably reduce all-cause mortality. Administration of 0.25 mg/kg tenecteplase after acute ischemic stroke is suggestive of increasing the proportion of patients that achieve excellent functional outcome at 3 months. (Source: Journal of Neurology)
Source: Journal of Neurology - March 4, 2024 Category: Neurology Source Type: research
